Related Experiment Videos

Molecular determinants of the cardiometabolic phenotype

Lisa de las Fuentes1, Giovanni de Simone, Donna K Arnett

  • 1Cardiovascular Imaging and Clinical Research Core Laboratory, Cardiovascular Division, Washington University School of Medicine, St. Louis, MO 63110, USA. lfuentes@wustl.edu

Endocrine, Metabolic & Immune Disorders Drug Targets
|April 14, 2010
PubMed

Insights

Metabolic syndrome, a cluster of cardiovascular risk factors, involves inflammation and energy imbalance. Future treatments for cardiometabolic syndrome (CMS) should target key molecular pathways common to both processes.

Area of Science:

  • Cardiovascular Medicine
  • Metabolic Disorders
  • Pathophysiology

Background:

  • Metabolic syndrome is a recognized predictor of adverse cardiovascular outcomes.
  • The precise mechanisms underlying cardiometabolic syndrome (CMS) are not fully understood.
  • Two intersecting pathways involving inflammation and energy homeostasis are implicated in CMS pathophysiology.

Purpose of the Study:

  • To review the current understanding of CMS pathophysiology.
  • To identify key molecular pathways involved in CMS.
  • To inform future pharmacologic intervention strategies for CMS.

Main Methods:

  • Literature review of accumulating evidence on CMS.
  • Analysis of intersecting pathways related to inflammation and energy homeostasis.
  • Identification of molecular nodes for potential therapeutic targeting.

Main Results:

  • Evidence points to two intersecting pathways in CMS: inflammation and energy homeostasis.
  • These pathways are critical in the pathophysiology of cardiometabolic traits.
  • No current pharmacologic interventions specifically target CMS.

Conclusions:

  • Future drug development for CMS should focus on molecular targets at the intersection of inflammation and energy homeostasis pathways.
  • Understanding these pathways is crucial for developing effective CMS treatments.
  • Targeting these intersecting pathways may offer novel therapeutic strategies for CMS.

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...